Drugs / HepaStem
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03963921 | Apr 2019 → May 2020 | metabolic dysfunction-associated steatohepatitis | Cellaion SA | Completed | No outcome recorded |
| Phase 1/2 | NCT01765283 | Mar 2012 → Oct 2014 | Crigler-Najjar syndrome, urea cycle disorder | Cellaion SA | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04229901 | Jan 2020 → May 2024 | liver failure | Cellaion SA | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03884959 | Jul 2018 → Nov 2020 | urea cycle disorder | HLB Cell Co., Ltd. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02946554 | Dec 2016 → Jul 2019 | liver disorder | Cellaion SA | Completed | No outcome recorded |
| Phase 2 | NCT02489292 | Oct 2014 → Mar 2017 | urea cycle disorder | Cellaion SA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepaStem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04229901 ↗ |
| Modality | Cell therapy | “liver-derived MSCs” PMID 32028991 ↗ Feb 2020 |
| Route | Other | “during intraportal infusions” PMID 32028991 ↗ Feb 2020 |